Ryan Fiehler

Company: F-Star Therapeutics

Job title: Associate Director, Discovery

Seminars:

1:15 pm Next Generation Tetravalent Bispecific Antibodies for Cancer Immunotherapy 1:15 pm

Discover F-star’s unique approach to making bispecific tetravalent antibodies in the Fc Description of the process to produce a conditional CD137 agonist Fcab FS222 bispecific uses of the CD137 agonist Fcab, in combination with a PD-L1 targeting Fab Discuss the benefits of FS222 in being tetravalentRead more

day: Conference Day One